Skip to main content

Table 2 Association between basic characteristics and immune cells in the microenvironment

From: Immune cell concentrations among the primary tumor microenvironment in colorectal cancer patients predicted by clinicopathologic characteristics and blood indexes

Variable

N = 240

CD3+ T cells in the CT

CD3+ T cells in the IM

CD8+ T cells in the CT

CD8+ T cells in the IM

Immunoscore

Low

High

P

Low

High

P

Low

High

P

Low

High

P

Low

High

P

Sex

   

0.894

  

1.000

  

0.355

  

0.895

  

0.326

 Male

146

70 (49.3%)

72 (50.7%)

 

71 (50.0%)

71 (50.0%)

 

69 (47.3%)

77 (52.7%)

 

72 (49.3%)

74 (50.7%)

 

90 (63.4%)

52 (36.6%)

 

 Female

94

48 (51.1%)

46 (48.9%)

 

47 (50.0%)

47 (50.0%)

 

51 (54.3%)

43 (45.7%)

 

48 (51.1%)

46 (48.9%)

 

66 (70.2%)

28 (29.8%)

 

Age

   

0.354

  

0.015

  

0.355

  

0.041

  

0.011

 < 75

206

98 (48.5%)

104 (51.5%)

 

94 (46.5%)

108 (53.3%)

 

100 (48.5%)

106 (51.5%)

 

97 (47.1%)

109 (52.9%)

 

127 (62.9%)

75 (37.1%)

 

 ≥75

34

20 (58.8%)

14 (41.2%)

 

24 (70.6%)

10 (29.4%)

 

20 (58.8%)

14 (41.2%)

 

23 (67.6%)

11 (32.3%)

 

29 (85.3%)

5 (14.7%)

 

Location

   

0.464

  

0.661

  

0.312

  

0.014

  

0.020

 Right

66

35 (54.7%)

29 (45.3%)

 

34 (53.1%)

30 (46.9%)

 

37 (56.1%)

29 (43.9%)

 

42 (63.6%)

24 (37.4%)

 

50 (78.1%)

14 (21.9%)

 

 Left

174

83 (48.3%)

89 (51.7%)

 

84 (48.8%)

88 (51.2%)

 

83 (47.7%)

91 (52.3%)

 

78 (44.8%)

96 (55.2%)

 

106 (61.6%)

66 (38.4%)

 

Pathological differentiation

   

1.000

  

1.000

  

0.580

  

0.580

  

0.883

 Poor

77

38 (49.4%)

39 (50.6%)

 

39 (50.6%)

38 (49.4%)

 

36 (46.8%)

41 (53.2%)

 

36 (46.8%)

41 (53.2%)

 

50 (64.9%)

27 (35.1%)

 

 Moderate and well

163

80 (44.7%)

79 (55.3%)

 

79 (49.7%)

80 (50.3%)

 

84 (51.3%)

79 (48.7%)

 

84 (51.3%)

79 (48.7%)

 

106 (66.7%)

53 (33.3%)

 

T stage

   

0.480

  

0.672

  

0.034

  

0.572

  

0.453

 T1 + T2 + T3

154

75 (49.7%)

76 (50.3%)

 

76 (50.3%)

75 (49.7%)

 

82 (51.9%)

72 (48.1%)

 

72 (46.8%)

82 (53.2%)

 

102 (67.5%)

49 (32.5%)

 

 T4

74

40 (54.8%)

33 (44.6%)

 

39 (61.9%)

34 (38.1%)

 

28 (37.8%)

46 (62.2%)

 

38 (51.4%)

36 (48.6%)

 

45 (61.6%)

28 (38.4%)

 

 NA

12

               

N stage

   

0.060

  

0.080

  

0.566

  

0.774

  

0.221

 No

73

31 (43.7%)

40 (56.3%)

 

32 (45.1%)

39 (54.9%)

 

32 (43.8%)

41 (56.2%)

 

32 (43.8%)

41 (56.2%)

 

42 (59.2%)

29 (40.8%)

 

 N1 + N2

141

80 (57.6%)

59 (42.4%)

 

81 (58.2%)

58 (41.8%)

 

68 (48.2%)

73 (51.8%)

 

65 (46.1%)

76 (53.9%)

 

95 (68.3%)

44 (31.7%)

 

 NA

26

               

M stage

   

0.328

  

0.102

  

0.337

  

0.749

  

0.606

 M0

49

27 (57.4%)

20 (42.6%)

 

29 (61.7%)

18 (38.3%)

 

21 (42.9%)

28 (57.1%)

 

26 (53.1%)

23 (46.9%)

 

33 (70.2%)

14 (29.88%)

 

 M1

191

91 (47.6%)

98 (52.4%)

 

89 (47.1%)

100 (62.9%)

 

99 (51.8%)

92 (48.2%)

 

94 (49.2%)

97 (50.8%)

 

123 (65.1%)

66 (34.9%)

 

MS

   

0.429

  

1.000

  

0.682

  

1.000

  

1.000

 MSS

158

73 (47.4%)

81 (52.6%)

 

73 (47.4%)

81 (52.6%)

 

80 (50.6%)

78 (49.4%)

 

75 (47.5%)

83 (52.5%)

 

97 (61.4%)

57 (38.6%)

 

 MSI

6

4 (66.7%)

2 (33.3%)

 

3 (50%)

3 (50%)

 

2 (33.3%)

4 (66.7%)

 

3 (33.3%)

3 (33.3%)

 

4 (66.7%)

2 (33.3%)

 

 NA

76

               

KRAS

   

0.161

  

0.470

  

0.176

  

0.262

  

0.103

 W

48

15 (31.9%)

32 (68.1%)

 

15 (31.9%)

32 (68.1%)

 

21 (43.8%)

27 (56.2%)

 

21 (43.8%)

27 (56.2%)

 

22 (46.8%)

25 (53.2%)

 

 M

33

15 (48.4%)

16 (51.6%)

 

15 (45.5%)

18 (64.5%)

 

20 (60.6%)

13 (39.4%)

 

19 (57.6%)

14 (42.4%)

 

21 (67.7%)

10 (32.3%)

 

 NA

159

               
  1. CT core of the tumor, IM invasive margin, NA not applicable
Back to article page